ImaCor, the developer of the world’s only hemodynamic transesophageal echocardiography (hTEE) technology, will be showcasing Zura EVO1, its all-in-one platform for advanced hemodynamic management at three annual scientific meetings this month: EAST (Eastern Association for the Surgery of Trauma), SCCM (Society of Critical Care Medicine), and STS (Society of Thoracic Surgeons).
This marks the premier demonstration of the enhanced platform, a first-of-its-kind for hemodynamic management. The new capabilities are imaging features at 7 MHz and 18 cm depth, hemodynamic trending data of cardiac filling and function, and availability of a transthoracic echocardiography (TTE) probe for complementary hemodynamic management.
"Our customers are taking a disciplined approach to hemodynamics to help them manage their sickest patients, and we are committed to their successful implementations"
ImaCor’s all-in-one hemodynamic management platform offers hTEE, which is enabled by a miniaturized, disposable probe that can be left indwelling for up to 72 hours of direct continuous visualization.
Most recently, a retrospective analysis at St. George’s Healthcare NHS Trust, London, UK, demonstrated that 195 hTEE evaluations resulted in the change of therapy of 41 patients, which ultimately improved hemodynamic parameters in 80.5% of patients. RV failure was diagnosed in almost 70% of patients, of which hTEE had a direct therapeutic impact in 68%.